Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonsurf + Gemcitabine + Nab-Paclitaxel in Advanced PDAC
NCT04046887Phase 1Terminated
- Start
- Sep 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trifluridine + tipiracil in pancreatic ductal adenocarcinoma (PDAC). Primary endpoint: Dose Limiting Toxicities at 28 days. Started Sep 2019; status: terminated.
02
Drugs
trifluridine + tipiracil
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04046887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046887.